A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing

Viatris

Status: Completed

Conditions: Neuralgia, Postherpetic; Neuralgia

Treatments: Drug: 2-weeks placebo then gabapentin; Drug: 1-week placebo then gabapentin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00674687

A9451138

Details and patient eligibility

About

The purpose of this study is to assess the reproducibility and the effect of gabapentin on quantitative sensory testing assessments in neuropathic pain subjects.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neuropathic pain of peripheral origin as a consequence of either post-herpetic neuralgia or post-traumatic neuropathic pain
• Well-defined skin area of mechanical allodynia to punctate (von Frey filament) stimuli
• Pain intensity score of ≥ 4/10 for von Frey filament-evoked allodynia at the skin area

Exclusion criteria

• Patients who have undergone neurolytic or neurosurgical therapy, including skin excisions, for neuropathic pain
• Patients who have trigeminal neuralgia, central pain, chronic radiculopathy, or peripheral neuropathy of non-mechanical or unknown origin
• Patients with any other co-existing pain which cannot be differentiated from the neuropathic pain of peripheral origin

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Triple Blind

---

23 participants in 2 patient groups, including a placebo group

Sequence 1

Placebo Comparator group

Treatment:

Drug: 2-weeks placebo then gabapentin

Sequence 2

Experimental group

Treatment:

Drug: 1-week placebo then gabapentin